PHARBIOMED: what changed
PHARBIOMED
Largest movements
- Tangible fixed assets +€193,023
up €193,023 (+12,348%), from €1,563 to €194,586
of which Plant, machinery and equipment: +€193,429
- Cash +€44,394
up €44,394 (+76.3%), from €58,152 to €102,546
mainly Net result for the year (+€258,313) and Tax, wage and social debts (+€48,199)
- Receivables within one year -€34,680
down €34,680 (-54.4%), from €63,782 to €29,102
of which Trade receivables: -€30,607
- Profit (loss) carried forward +€208,313
new in 2025: €208,313
- Tax, wage and social debts +€48,199
up €48,199 (+118%), from €40,796 to €88,995
of which Taxes: +€44,207
- Other debts -€32,722
down €32,722 (-44.7%), from €73,245 to €40,522
- Advances received -€23,908
no longer reported in 2025 (was €23,908)
- Gross operating margin +€274,890
up €274,890 (+185%), from €148,672 to €423,562
- Taxes +€68,400
up €68,400 (+278%), from €24,615 to €93,015
- Staff costs +€24,738
up €24,738 (+66.7%), from €37,084 to €61,822
- Depreciation -€5,180
down €5,180 (-36.6%), from €14,163 to €8,984
Change in the result, 2024 to 2025
For each income-statement line you see the change as its effect on the result. Higher costs lower the result, higher income raises it.
Derived cash bridge
The bridge is derived from the 2024 and 2025 balance sheets and the 2025 result. There is no filed cash-flow statement. You see where the money came from and where it went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €170,401 | €369,863 | +€199,461 | +117% |
| Fixed assets | 21/28 | €2,738 | €194,586 | +€191,848 | +7,007% |
| Intangible fixed assets | 21 | €1,175 | - | -€1,175 | |
| Tangible fixed assets | 22/27 | €1,563 | €194,586 | +€193,023 | +12,348% |
| Plant, machinery and equipment | 23 | - | €193,429 | +€193,429 | |
| Furniture and vehicles | 24 | €1,563 | €1,157 | -€407 | -26.0% |
| Current assets | 29/58 | €167,663 | €175,277 | +€7,614 | +4.5% |
| Stocks and contracts in progress | 3 | €41,608 | €39,431 | -€2,177 | -5.2% |
| Stocks | 30/36 | €41,608 | €39,431 | -€2,177 | -5.2% |
| Amounts receivable within one year | 40/41 | €63,782 | €29,102 | -€34,680 | -54.4% |
| Trade receivables | 40 | €47,978 | €17,371 | -€30,607 | -63.8% |
| Other amounts receivable | 41 | €15,803 | €11,730 | -€4,073 | -25.8% |
| Cash at bank and in hand | 54/58 | €58,152 | €102,546 | +€44,394 | +76.3% |
| Deferred charges and accrued income | 490/1 | €4,122 | €4,198 | +€76 | +1.9% |
| Total equity and liabilities | 10/49 | €170,401 | €369,863 | +€199,461 | +117% |
| Equity | 10/15 | €27,489 | €235,802 | +€208,313 | +758% |
| Contributions | 10/11 | €18,600 | €18,600 | = | 0.0% |
| Reserves | 13 | €8,889 | €8,889 | = | 0.0% |
| Non-distributable reserves | 130/1 | €1,860 | €1,860 | = | 0.0% |
| Reserves not available under the articles | 1311 | €1,860 | €1,860 | = | 0.0% |
| Tax-exempt reserves | 132 | €7,029 | €7,029 | = | 0.0% |
| Profit (loss) carried forward | 14 | - | €208,313 | +€208,313 | |
| Amounts payable | 17/49 | €142,912 | €134,061 | -€8,852 | -6.2% |
| Amounts payable within one year | 42/48 | €142,912 | €134,061 | -€8,852 | -6.2% |
| Trade debts | 44 | €4,964 | €4,543 | -€421 | -8.5% |
| Suppliers | 440/4 | €4,964 | €4,543 | -€421 | -8.5% |
| Advances received on contracts in progress | 46 | €23,908 | - | -€23,908 | |
| Taxes, remuneration and social security | 45 | €40,796 | €88,995 | +€48,199 | +118% |
| Taxes | 450/3 | €33,808 | €78,015 | +€44,207 | +131% |
| Remuneration and social security | 454/9 | €6,988 | €10,980 | +€3,992 | +57.1% |
| Other amounts payable | 47/48 | €73,245 | €40,522 | -€32,722 | -44.7% |
| Remuneration, social security and pensions | 62 | €37,084 | €61,822 | +€24,738 | +66.7% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €14,163 | €8,984 | -€5,180 | -36.6% |
| Other operating charges | 640/8 | €615 | €633 | +€18 | +2.9% |
| Gross operating margin | 9900 | €148,672 | €423,562 | +€274,890 | +185% |
| Operating profit (loss) | 9901 | €96,809 | €352,123 | +€255,313 | +264% |
| Financial income | 75/76B | €0 | €0 | -€0 | -58.1% |
| Recurring financial income | 75 | €0 | €0 | -€0 | -58.1% |
| Financial charges | 65/66B | €982 | €795 | -€187 | -19.1% |
| Recurring financial charges | 65 | €982 | €795 | -€187 | -19.1% |
| Profit (loss) for the period before taxes | 9903 | €95,828 | €351,328 | +€255,500 | +267% |
| Income taxes | 67/77 | €24,615 | €93,015 | +€68,400 | +278% |
| Profit (loss) for the period | 9904 | €71,213 | €258,313 | +€187,100 | +263% |
| Profit (loss) for the period to be appropriated | 9905 | €71,213 | €258,313 | +€187,100 | +263% |
Next steps
Calculation and sources
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Green is a favourable move for that line, red an unfavourable one. Prepared on 7 November 2026 via checked.be.